Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats
| dc.accessRights | Anonymous | * |
| dc.audience | Science | en_US |
| dc.contributor.author | Koehl, Niklas | |
| dc.contributor.author | Kuentz, Martin | |
| dc.date.accessioned | 2021-05-10T07:37:55Z | |
| dc.date.available | 2021-05-10T07:37:55Z | |
| dc.date.issued | 2020-06-10 | |
| dc.description.abstract | Conclusion: Chase dosed LBF enhanced the in vivo bioavailability of nilotinib. Long chain lipids showed superior performance compared to medium chain lipids. Chase dosing appeared to prolong the absorption phase of the drug. Therefore, chase dosing of LBF is favourable compared to lipid suspensions for 'brick dust' molecules such as nilotinib. Graphical Abstract The potential of bio-enabling lipid vehicles, administered via chase dosing and lipid suspensions, has been evaluated as an approach to enhance oral bioavailability of nilotinib. | en_US |
| dc.description.uri | https://pubmed.ncbi.nlm.nih.gov/32524365/ | en_US |
| dc.identifier.doi | 10.1007/s11095-020-02841-9 | |
| dc.identifier.issn | 0724-8741 | |
| dc.identifier.issn | 1573-904X | |
| dc.identifier.uri | https://irf.fhnw.ch/handle/11654/32421 | |
| dc.issue | 7 | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Springer | en_US |
| dc.relation.ispartof | Pharmaceutical Research | en_US |
| dc.subject | brick dust molecule | en_US |
| dc.subject | chase dosing | en_US |
| dc.subject | lipid based formulation | en_US |
| dc.subject | poorly water-soluble drugs | en_US |
| dc.title | Chase Dosing of Lipid Formulations to Enhance Oral Bioavailability of Nilotinib in Rats | en_US |
| dc.type | 01A - Beitrag in wissenschaftlicher Zeitschrift | |
| dc.volume | 37 | en_US |
| dspace.entity.type | Publication | |
| fhnw.InventedHere | Yes | en_US |
| fhnw.IsStudentsWork | no | en_US |
| fhnw.PublishedSwitzerland | Yes | en_US |
| fhnw.ReviewType | Anonymous ex ante peer review of a complete publication | en_US |
| fhnw.affiliation.hochschule | Hochschule für Life Sciences FHNW | de_CH |
| fhnw.affiliation.institut | Institut für Pharma Technology | de_CH |
| fhnw.pagination | 124 | en_US |
| fhnw.publicationOnline | Ja | en_US |
| fhnw.publicationState | Published | en_US |
| relation.isAuthorOfPublication | 68819448-8611-488b-87bc-1b1cf9a6a1b4 | |
| relation.isAuthorOfPublication.latestForDiscovery | 68819448-8611-488b-87bc-1b1cf9a6a1b4 |